A
Axsome Therapeutics Inc (AXSM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$141.69
-2.68 (-1.86%)
Market Cap: $7.45B
Last updated: Nov 17, 2026 at 11:05 AM ET
Axsome Therapeutics Inc (AXSM) Valuation Multiples
Axsome Therapeutics (AXSM) trades at 8.6x sales and 70.5x book value. Its P/S of 8.6x is below its 5-year median of 13.9x. Its forward P/E is 29.5x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 29.5x |
| Price to sales | 8.6x |
| Price to book | 70.5x |
| PEG | N/A |
| FCF yield | -1.1% |
Historical Medians
Against its 10-year medians, its P/B is 145.6% above 28.7x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 8.6x | 13.9x | N/A |
| P/B | 70.5x | 67.1x | 28.7x |
Valuation History
Over the 4 of the 10 year ends shown that have a P/S, its P/S ranged from 10.5x in 2024 to 64.8x in 2022.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $182.64 | 14.3x | 104.7x |
| 2024 | $84.61 | 10.5x | 72.0x |
| 2023 | $79.59 | 13.3x | 19.7x |
| 2022 | $77.13 | 64.8x | 30.6x |
| 2021 | $37.78 | N/A | 91.3x |
| 2020 | $81.47 | N/A | 26.7x |
| 2019 | $103.36 | N/A | N/A |
| 2018 | $2.82 | N/A | 89.8x |
| 2017 | $5.60 | N/A | 8.1x |
| 2016 | $6.75 | N/A | 6.0x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About AXSM
What is AXSM's forward P/E ratio?
Axsome Therapeutics has a forward P/E ratio of 29.5x.
Is AXSM stock overvalued?
GNG's valuation label for AXSM is Fairly valued.
What is AXSM's price to sales ratio?
Axsome Therapeutics has a price to sales ratio of 8.6x.
AXSM pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors